Intravenous Iron Therapy: Re-administration after Prior Adverse Reaction

被引:2
作者
Aung, Tim [1 ,2 ,3 ,6 ]
Thein, Hla [4 ]
Aung, Sandy Tin [5 ]
Soe, Benjamin Tin Aung
Ohnmar, Ei [7 ]
机构
[1] Royal Australian Coll Gen Practitioners, Melbourne, Vic, Australia
[2] Star Med Ctr, Logan, Qld, Australia
[3] Star Med Ctr, Brisbane, Qld, Australia
[4] Middlemore Hosp, Renal Dept, Cty Manukau Hlth, Auckland, New Zealand
[5] Logan Hosp, Pharm Dept, Logan, Qld, Australia
[6] Turuki Hlth Care Indigenous, Auckland, New Zealand
[7] Bank St Med, Whangarei, New Zealand
关键词
Intravenous Iron; Iron Infusion; Intravenous Iron Reactions; Rechallenge of Intravenous Iron; Re-ad-ministration of intravenous iron; Fishbane Reaction; HYPERSENSITIVITY REACTIONS; SAFETY; RISK; DEFICIENCY; MANAGEMENT; INFUSION; DEXTRAN;
D O I
10.4082/kjfm.23.0039
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Intravenous (IV) iron therapy is performed in community practices and hospitals with modern formulations when oral administration becomes impractical. Effective replacement of iron is important for the treatment of iron deficiency and anemia. Can IV iron be rechallenged in individuals with a history of adverse reactions? This review is to explore the challenge of this, when clinically indicated.Methods: After performing a literature search, five studies (combined total sample number=1,006) for re-exposure of IV iron to individuals with a history of past reactions were identified, observed, and analyzed. Re-exposure included reactions ranging from mild to moderate and few cases of severe type.Results: The majority (>80%) of IV iron rechallenges were tolerable, safe, and successful without major serious incidents. There were no reports of major reactions (severe hypersensitivity reactions or anaphylaxis) in these re-exposures.Conclusion: Re-administration of IV iron therapy in patients with a previous adverse reaction is plausible, with benefit and risk stratification. A rechallenge would depend on the nature and degree of the adverse reaction and use of alternative formulations. Rechallenge to a previous severe hypersensitivity reaction or anaphylaxis with the same product has not been reported in these studies. Evidence on the benefit of premedication use is conflicting and requires further studies.
引用
收藏
页码:350 / 354
页数:5
相关论文
共 20 条
[1]   Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions [J].
Arastu, Asad H. ;
Elstrott, Benjamin K. ;
Martens, Kylee L. ;
Cohen, Jonathan L. ;
Oakes, Michael H. ;
Rub, Zhoe T. ;
Aslan, Joseph J. ;
DeLoughery, Thomas G. ;
Shatzel, Joseph .
JAMA NETWORK OPEN, 2022, 5 (03)
[2]   Single-dose intravenous iron for iron deficiency: a new paradigm [J].
Auerbach, Michael ;
Deloughery, Thomas .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, :57-66
[3]  
Aung T, 2021, NEW ZEAL MED J, V134, P118
[4]   The Safety of Intravenous Iron Preparations: Systematic Review and Meta-analysis [J].
Avni, Tomer ;
Bieber, Amir ;
Grossman, Alon ;
Green, Hefziba ;
Leibovici, Leonard ;
Gafter-Gvili, Anat .
MAYO CLINIC PROCEEDINGS, 2015, 90 (01) :12-23
[5]   Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety [J].
Blumenstein, Irina ;
Shanbhag, Satish ;
Langguth, Peter ;
Kalra, Philip A. ;
Zoller, Heinz ;
Lim, Wendy .
EXPERT OPINION ON DRUG SAFETY, 2021, 20 (07) :757-769
[6]   World allergy organization anaphylaxis guidance 2020 [J].
Cardona, Victoria ;
Ansotegui, Ignacio J. ;
Ebisawa, Motohiro ;
El-Gamal, Yehia ;
Fernandez Rivas, Montserrat ;
Fineman, Stanley ;
Geller, Mario ;
Gonzalez-Estrada, Alexei ;
Greenberger, Paul A. ;
Sanchez Borges, Mario ;
Senna, Gianenrico ;
Sheikh, Aziz ;
Kase Tanno, Luciana ;
Thong, Bernard Y. ;
Turner, Paul J. ;
Worm, Margitta .
WORLD ALLERGY ORGANIZATION JOURNAL, 2020, 13 (10)
[7]   Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review [J].
Choo, K. J. L. ;
Simons, E. ;
Sheikh, A. .
ALLERGY, 2010, 65 (10) :1205-1211
[8]   Risks for Anaphylaxis With Intravenous Iron Formulations A Retrospective Cohort Study [J].
Dave, Chintan, V ;
Brittenham, Gary M. ;
Carson, Jeffrey L. ;
Setoguchi, Soko .
ANNALS OF INTERNAL MEDICINE, 2022, 175 (05) :656-+
[9]  
European Medicines Agency, 2013, Assessment report for: iron containing intravenous (IV) medicinal products: EMEA/H/A-31/1322
[10]   The safety of intravenous iron dextran in hemodialysis patients [J].
Fishbane, S ;
Ungureanu, VD ;
Maesaka, JK ;
Kaupke, CJ ;
Lim, V ;
Wish, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (04) :529-534